These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 1814194)
1. FDA's role in drug product recalls. Crawford SY Am J Hosp Pharm; 1991 Dec; 48(12):2595-6. PubMed ID: 1814194 [No Abstract] [Full Text] [Related]
2. FDA's regulation of prescription drug labeling: a role for implied preemption. Kendrick LC Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031 [No Abstract] [Full Text] [Related]
3. The learned intermediary doctrine: past, present and future. Alsobrook HB Leg Med; 1994; ():269-80. PubMed ID: 7830482 [No Abstract] [Full Text] [Related]
5. The FDA's restrictions against prescription drug advertising: more hindrance than help. Lorman AJ Healthspan; 1991 Nov; 8(10):3-7. PubMed ID: 10114942 [No Abstract] [Full Text] [Related]
6. FDA attempting to overcome major roadblocks in monitoring drug safety. Zielinski SL J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645 [No Abstract] [Full Text] [Related]
7. Regulatory experts debate FDA's authority. Young D Am J Health Syst Pharm; 2007 May; 64(9):910, 912. PubMed ID: 17468140 [No Abstract] [Full Text] [Related]
8. Processing and evaluation of adverse drug experience reports at the Food and Drug Administration Center for Veterinary Medicine. Keller WC; Bataller N; Oeller DS J Am Vet Med Assoc; 1998 Jul; 213(2):208-11. PubMed ID: 9676589 [No Abstract] [Full Text] [Related]
12. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate. Dorfman HL; Quinn VM; Brophy EA Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765 [No Abstract] [Full Text] [Related]
13. Prescription for the Orphan Drug Act: the impact of the FDA's 1992 regulations and the latest congressional proposals for reform. Clissold DB Food Drug Law J; 1995; 50(1):125-47. PubMed ID: 10342989 [No Abstract] [Full Text] [Related]
14. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation? Orlando VI Am J Law Med; 1999; 25(4):543-68. PubMed ID: 10629734 [No Abstract] [Full Text] [Related]
15. Drug industry trying to change FDA's slow but sure policy. Demkovich LE Natl J (Wash); 1979 Jul; 11(29):1211-5. PubMed ID: 10242491 [No Abstract] [Full Text] [Related]
16. Bringing the FDA's Information to Market. Woloshin S; Schwartz LM Arch Intern Med; 2009 Nov; 169(21):1985-7. PubMed ID: 19933960 [No Abstract] [Full Text] [Related]
17. Drug safety special: chasing shadows. Frantz S Nature; 2005 Mar; 434(7033):557-8. PubMed ID: 15800592 [No Abstract] [Full Text] [Related]
18. MedWatch. FDA's 'heads up' on medical product safety. Henkel J FDA Consum; 1998; 32(6):10-2, 15. PubMed ID: 9854445 [No Abstract] [Full Text] [Related]
19. Access to safety data--stockholders versus prescribers. Pfeffer MA; Bowler MB N Engl J Med; 2011 Jul; 365(1):1-3. PubMed ID: 21714642 [No Abstract] [Full Text] [Related]
20. Vioxx, radiology, and the Food and Drug Administration. Pentecost MJ J Am Coll Radiol; 2005 May; 2(5):394-7. PubMed ID: 17411841 [No Abstract] [Full Text] [Related] [Next] [New Search]